Cargando…

Trial Watch: DNA vaccines for cancer therapy

During the past 2 decades, the possibility that preparations capable of eliciting tumor-specific immune responses would mediate robust therapeutic effects in cancer patients has received renovated interest. In this context, several approaches to vaccinate cancer patients against their own malignanci...

Descripción completa

Detalles Bibliográficos
Autores principales: Pol, Jonathan, Bloy, Norma, Obrist, Florine, Eggermont, Alexander, Galon, Jérôme, Hervé Fridman, Wolf, Cremer, Isabelle, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008456/
https://www.ncbi.nlm.nih.gov/pubmed/24800178
http://dx.doi.org/10.4161/onci.28185
_version_ 1782314453357821952
author Pol, Jonathan
Bloy, Norma
Obrist, Florine
Eggermont, Alexander
Galon, Jérôme
Hervé Fridman, Wolf
Cremer, Isabelle
Zitvogel, Laurence
Kroemer, Guido
Galluzzi, Lorenzo
author_facet Pol, Jonathan
Bloy, Norma
Obrist, Florine
Eggermont, Alexander
Galon, Jérôme
Hervé Fridman, Wolf
Cremer, Isabelle
Zitvogel, Laurence
Kroemer, Guido
Galluzzi, Lorenzo
author_sort Pol, Jonathan
collection PubMed
description During the past 2 decades, the possibility that preparations capable of eliciting tumor-specific immune responses would mediate robust therapeutic effects in cancer patients has received renovated interest. In this context, several approaches to vaccinate cancer patients against their own malignancies have been conceived, including the administration of DNA constructs coding for one or more tumor-associated antigens (TAAs). Such DNA-based vaccines conceptually differ from other types of gene therapy in that they are not devised to directly kill cancer cells or sensitize them to the cytotoxic activity of a drug, but rather to elicit a tumor-specific immune response. In spite of an intense wave of preclinical development, the introduction of this immunotherapeutic paradigm into the clinical practice is facing difficulties. Indeed, while most DNA-based anticancer vaccines are well tolerated by cancer patients, they often fail to generate therapeutically relevant clinical responses. In this Trial Watch, we discuss the latest advances on the use of DNA-based vaccines in cancer therapy, discussing the literature that has been produced around this topic during the last 13 months as well as clinical studies that have been launched in the same time frame to assess the actual therapeutic potential of this intervention.
format Online
Article
Text
id pubmed-4008456
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40084562015-04-01 Trial Watch: DNA vaccines for cancer therapy Pol, Jonathan Bloy, Norma Obrist, Florine Eggermont, Alexander Galon, Jérôme Hervé Fridman, Wolf Cremer, Isabelle Zitvogel, Laurence Kroemer, Guido Galluzzi, Lorenzo Oncoimmunology Review During the past 2 decades, the possibility that preparations capable of eliciting tumor-specific immune responses would mediate robust therapeutic effects in cancer patients has received renovated interest. In this context, several approaches to vaccinate cancer patients against their own malignancies have been conceived, including the administration of DNA constructs coding for one or more tumor-associated antigens (TAAs). Such DNA-based vaccines conceptually differ from other types of gene therapy in that they are not devised to directly kill cancer cells or sensitize them to the cytotoxic activity of a drug, but rather to elicit a tumor-specific immune response. In spite of an intense wave of preclinical development, the introduction of this immunotherapeutic paradigm into the clinical practice is facing difficulties. Indeed, while most DNA-based anticancer vaccines are well tolerated by cancer patients, they often fail to generate therapeutically relevant clinical responses. In this Trial Watch, we discuss the latest advances on the use of DNA-based vaccines in cancer therapy, discussing the literature that has been produced around this topic during the last 13 months as well as clinical studies that have been launched in the same time frame to assess the actual therapeutic potential of this intervention. Landes Bioscience 2014-04-01 /pmc/articles/PMC4008456/ /pubmed/24800178 http://dx.doi.org/10.4161/onci.28185 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Review
Pol, Jonathan
Bloy, Norma
Obrist, Florine
Eggermont, Alexander
Galon, Jérôme
Hervé Fridman, Wolf
Cremer, Isabelle
Zitvogel, Laurence
Kroemer, Guido
Galluzzi, Lorenzo
Trial Watch: DNA vaccines for cancer therapy
title Trial Watch: DNA vaccines for cancer therapy
title_full Trial Watch: DNA vaccines for cancer therapy
title_fullStr Trial Watch: DNA vaccines for cancer therapy
title_full_unstemmed Trial Watch: DNA vaccines for cancer therapy
title_short Trial Watch: DNA vaccines for cancer therapy
title_sort trial watch: dna vaccines for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008456/
https://www.ncbi.nlm.nih.gov/pubmed/24800178
http://dx.doi.org/10.4161/onci.28185
work_keys_str_mv AT poljonathan trialwatchdnavaccinesforcancertherapy
AT bloynorma trialwatchdnavaccinesforcancertherapy
AT obristflorine trialwatchdnavaccinesforcancertherapy
AT eggermontalexander trialwatchdnavaccinesforcancertherapy
AT galonjerome trialwatchdnavaccinesforcancertherapy
AT hervefridmanwolf trialwatchdnavaccinesforcancertherapy
AT cremerisabelle trialwatchdnavaccinesforcancertherapy
AT zitvogellaurence trialwatchdnavaccinesforcancertherapy
AT kroemerguido trialwatchdnavaccinesforcancertherapy
AT galluzzilorenzo trialwatchdnavaccinesforcancertherapy